Hinge Health Tagged a Record $95.57 and Got Rejected in One Day — $87.06 Decides Whether the Top Is In

HNGE closed Friday at $87.35, down 5.92%, on roughly double the volume of the session that made its record. One day after touching the highest price in its short public life, the stock reversed hard and trapped the buyers who chased it. Whatever comes next runs through a single number: $87.06.

The setup, as of the Friday, August 28, 2026, close.

The 48 hours that flipped the chart

Hinge Health just demonstrated what a record high is worth when nobody steps up to defend it. Thursday, HNGE touched $95.57 on 1.6 million shares — the highest print since the company went public in May 2025 at $32 a share. Friday, it closed at $87.35, down 5.92%, within 29 cents of its session low of $87.06. No downgrade touched the tape. No guidance cut hit the wires. The chart reversed itself.

The two sessions could not have left more different signatures. Thursday's record was made on light participation for a stock making history. Friday's reversal ran on 2.997 million shares and roughly $265 million of turnover, close to two times the share count of the session that made the high. Breakouts need marginal buyers; they were absent at the moment the high printed and present in force the moment it broke. That mismatch — a weak-thrust high and a high-participation reversal — is the signature of supply arriving at the top, not a routine pause.

Why anyone bought it in the first place

This is not a speculative shell. Hinge Health automates musculoskeletal care — digital physical therapy for back and joint pain, delivered through an AI platform and paid for by employers and health plans — and the market has re-rated it hard. The stock's 52-week range is $30.08 to $95.57, roughly triple its IPO price, and it got there on real numbers.

The fuel was a second quarter reported August 4: revenue of $212.8 million, up 53 percent, and full-year 2026 guidance raised to $856 million to $860 million. That came in well above the $822 million Wall Street had modeled. Shares jumped double digits on the reaction to the report, and the stock sits on Investor's Business Daily's IPO Leaders screen. That is the backdrop: flawless earnings, raised guidance, a fast expansion into digestive care — and a stock that could not hold its own record high for even one session.

The line: $87.06

Everything now runs through $87.06, Friday's low, and it has company. The 50-day moving average sits at $83.31, and under that an early-August shelf near $80 — the stock's intraday low on August 7 was $80.66 — marks where buyers co-existed before the final leg. The 200-day at $55.55 shows how much air the chart has below; none of it is reachable without first breaking this advance.

Hold $87.06 and this is a first pullback inside a powerful trend: a close back above $92.85 to $93.50, the bottom of last week's failed zone, would clear the distribution read, and a fresh close above $95.57 would turn Thursday's rejection into a head-fake. Lose $87.06 and the nearest honest support is the 50-day at $83.31, with the $80 shelf under that.

What traders are missing

Three things keep this from being a forgettable profit-taking day.

First, the volume divergence cuts against the bull case. A record high printed on the weakest participation of the recent run; the reversal printed on the strongest. When a breakout can't attract buyers at the margin, the marginal trade turns short.

Second, this reversal just trapped the most recent inventory. Anyone who chased above $90 over the past week bought a move that failed within 24 hours and is now about 8 percent underwater from the $95.57 peak. That is not support; it is supply that has to be worked through on any bounce, and it weighs on every reclaim attempt.

Third, the news was already in the price. The stock failed at its high after a beat-and-raise, and its 14-day momentum gauge has cooled to 53 — the buyers stopped leaning before the level broke, not after. When a stock stops responding to good news, the next hand belongs to the sellers.

The other side of the line

None of this argues the company story is broken. Growth is 53 percent, guidance is climbing, and the Cylinder Health deal pushes it beyond musculoskeletal care into a wider chronic-care platform. The bear case is a chart-and-valuation verdict, not a business verdict: at roughly $7.5 billion in market value and near 68 times trailing earnings, the stock is priced to perfect execution. When the price fails to hold its high despite the numbers, the question shifts from the story to the multiple — and the tape becomes the messenger.

Trade map

Scenario	Trigger	Path	Invalidation	Horizon
Distribution continues	Daily close below $87.06	50-day at $83.31, then the ~$80 shelf	Close back above $93.50	Days to weeks
Dip gets bought	$87.06 holds; close above $92.85	Reclaim and retest of $95.57	Daily close below $87.06	Days to weeks

The verdict

Hold $87.06 and this is a pause inside an uptrend, with the sellers on the failed high forced to chase on a reclaim. Lose $87.06 and the record becomes rejected supply, and the 50-day at $83.31 is the first test of how much of the near-triple is real. The setup has until the next few daily closes to prove itself. This is a price decision, decided by the tape — the story already had its day.